Avidity Biosciences Inc [RNA] stock is trading at $30.08, down -2.46%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RNA shares have gain 11.20% over the last week, with a monthly amount drifted -2.02%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Avidity Biosciences Inc [NASDAQ: RNA] stock has seen the most recent analyst activity on December 20, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $72. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on November 26, 2024, and set its price target to $67. On September 24, 2024, Goldman initiated with a Buy rating and assigned a price target of $59 on the stock. Barclays started tracking the stock assigning a Overweight rating and suggested a price target of $63 on August 28, 2024. BofA Securities initiated its recommendation with a Buy and recommended $40 as its price target on May 03, 2024. Cantor Fitzgerald started tracking with a Overweight rating for this stock on March 14, 2024, and assigned it a price target of $60. In a note dated May 22, 2023, Evercore ISI upgraded an Outperform rating on this stock but restated the target price of $20.
Avidity Biosciences Inc [RNA] stock has fluctuated between $9.93 and $56.00 over the past year. Currently, Wall Street analysts expect the stock to reach $59 within the next 12 months. Avidity Biosciences Inc [NASDAQ: RNA] shares were valued at $30.08 at the most recent close of the market. An investor can expect a potential return of 96.14% based on the average RNA price forecast.
Analyzing the RNA fundamentals
Avidity Biosciences Inc [NASDAQ:RNA] reported sales of 10.12M for the trailing twelve months, which represents a drop of -17.10%. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -32.09%, Pretax Profit Margin comes in at -27.72%, and Net Profit Margin reading is -27.72%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.28 and Total Capital is -0.21. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.10 points at the first support level, and at 28.13 for the second support level. However, for the 1st resistance point, the stock is sitting at 31.46, and for the 2nd resistance point, it is at 32.85.
Ratios To Look Out For
For context, Avidity Biosciences Inc’s Current Ratio is 17.76. Also, the Quick Ratio is 17.76, while the Cash Ratio stands at 4.05. Considering the valuation of this stock, the price to sales ratio is 354.63, the price to book ratio is 2.38.
Transactions by insiders
Recent insider trading involved KATHLEEN GALLAGHER, Officer, that happened on Jan 22 ’25 when 6924.0 shares were purchased. CSTO, Flanagan W. Michael completed a deal on Dec 18 ’24 to sell 12742.0 shares. Meanwhile, Chief Financial Officer MacLean Michael F sold 11151.0 shares on Dec 18 ’24.
